Publicaties

Zie deze Pubmed-link voor een compleet overzicht van internationale wetenschappelijke publicaties.

Top publicaties

Bhattacharyya S., Appiah-Kusi E., Wilson R., O’Neill A., Brammer M., Williams S., Perez J., Bossong M.G., McGuire P. (2024) Effects of cannabidiol on symptoms in people at clinical high risk for psychosis. World Psychiatry 23, 451-452. IF 60.5, cites 2

van Boxel R., Gangadin S.S., Janssen H., van der Steur S., van der Vinne L.J.C., Dortants L., Pelgrim T.A.D., Draisma L.W.R., Tuura R., van der Meer P., Batalla A., Bossong M.G. (2023) The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder. J Psychiatr Res. 163, 93-101. IF 3.7, cites 8

Bossong M.G., Antoniades M., Azis M., Samson C., Quinn B., Bonoldi I., Modinos G., Pérez J., Howes O.D., Stone J., Allen P., McGuire P. (2019) Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry 76, 199-207. IF 22.5, cites 58

Bhattacharyya S., Wilson R., Appiah-Kusi E., O’Neill A., Brammer M., Perez J., Murray R., Allen P., Bossong M.G., McGuire P. (2018) Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial. JAMA Psychiatry 75, 1107-17. IF 22.5, cites 103

Bloomfield M.A.P., Hindocha C., Green S.F., Wall M.B., Lees R., Petrilli K., Costello H., Ogunbiyi M.O., Bossong M.G., Freeman T.P. (2018) The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther 195, 132-61 IF 12.0, cites 156

Iseger T.A., Bossong M.G. (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162, 153-61. IF 3.6, cites 182

Bossong M.G., Jansma J.M., Van Hell H.H., Jager G., Oudman E., Saliasi E., Kahn R.S., Ramsey N.F. (2012) Effects of Δ9-tetrahydrocannabinol on human working memory function. Biol Psychiatry 71, 693-9. IF 9.6, cites 76

Bossong M.G., Niesink R.J. (2010) Adolescent brain maturation, the endogenous cannabinoid system and cannabis-induced schizophrenia. Prog Neurobiol 92, 370-85. IF 6.7, cites 223

Bossong M.G., Van Berckel B.N.M., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., Van Gerven J.M.A., Ramsey N.F., Lammertsma A.A., Kahn R.S. (2009) ∆9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759-66. IF 6.6, cites 306

Van Berckel B.N.M., Bossong M.G., Van Haaren N., Boellaard R., Comans E.F.I., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. (2008) Microglia activation in recent onset schizophrenia: a quantitative (R)-[¹¹C]PK11195 PET study. Biol Psychiatry 64, 820-2. IF 9.6, cites 479

2025

Knight S.R., Abbasova L., Zeighami Y., Hansen J.Y., Martins D., Zelaya F., Dipasquale O., Liu T., Shin D., Bossong M., Azis M., Antoniades M., Howes O.D., Bonoldi I., Egerton A., Allen P., O’Daly O., McGuire P., Modinos G. (2025) Transcriptional and neurochemical signatures of cerebral blood flow alterations in schizophrenia and individuals at clinical high-risk for psychosis. Biol Psychiatry Online ahead of print. IF 9.6

Winter-van Rossum I., Slot M.I.E., van Hell H.H., Bossong M.G., Berger G., Aschauer H., Maat A., Walitza S., Lavan O., Baeza I., Dolz M., Monducci E., Fiori Nastro P., Kroken R.A., Lawrie S.M., et al. (2025) Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial. Schizophrenia Bulletin 51, 1082-91. IF 5.3 cites 1

2024

Leen M.A., Kowal M.A., Batalla A., Bossong M.G. (2024) The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review. Frontiers in Pharmacology 15, 1411631. IF 4.4 cites 0

Davies C., Bossong M.G., Martins D., Wilson R., Appiah-Kusi E., Blest-Hopley G., Zelaya F., Allen P., Brammer M., Perez J., McGuire P., Bhattacharyya S. (2024) Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol. Psychological Medicine 54, 993-1003. IF 5.9 cites 2

2023

Davies C., Bossong M.G., Martins D., Wilson R., Appiah-Kusi E., Blest-Hopley G., Allen P., Zelaya F., Lythgoe D.J., Brammer M., Perez J., McGuire P., Bhattacharyya S. (2023) Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk. Schizophrenia Bull Open 4, sgad022. cites 1

Pelgrim T.A.D., Ramaekers J.G., Wall M.B., Freeman T.P., Bossong M.G. (2023) Acute effects of Δ9-tetrahydrocannabinol (THC) on resting state connectivity networks and impact of COMT genotype: A multi-site pharmacological fMRI study. Drug Alcohol Depend 251, 110925. IF 3.9 cites 1

van der Meer P.B., Fuentes J.J., Kaptein A.A., Schoones J.W., de Waal M.M., Goudriaan A.E., Kramers K., Schellekens A., Somers M., Bossong M.G., Batalla A. (2023) Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry 14,  1134454. IF 3.2 cites 34

2022

Gunasekera B., Davies C., Blest-Hopley G., Veronese M., Ramsey N.F., Bossong M.G., Radua J., Bhattacharyya S., CBE Consortium (2022) Task-independent acute effects of delta-9-tetrahydrocannabinol on human brain function and its relationship with cannabinoid receptor gene expression: A neuroimaging meta-regression analysis. Neurosci Biobehav Rev 140, 104801. IF 7.6 cites 4

Tognin S., Richter A., Kempton M.J., Modinos G., Antoniades M., Azis M., Allen P., Bossong M.G., Perez J., Pantelis C., Nelson B., Amminger P., Riecher-Rössler A., Barrantes-Vidal N., Krebs M.O., Glenthøj B., Ruhrmann S., Sachs G., Rutten B.P.F., de Haan L., van der Gaag M., EU-GEI High Risk Study Group, Valmaggia L.R., McGuire P. (2022) The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis. Schizophr Bull Open 3, sgac040. cites 3

Vissink C.E., Winter-van Rossum I., Cannon T.D., Fusar-Poli P., Kahn R.S, Bossong M.G. (2022) Structural Brain Volumes of Individuals at Clinical High Risk for Psychosis: A Meta-analysis. Biological Psychiatry: Global Open Science, 2 (2), 147-152. IF 4.0 cites 15

2021

Modinos G., Richter A., Egerton A., Bonoldi I., Azis M., Antoniades M., Bossong M., Crossley N., Perez J., Stone J.M., Veronese M., Zelaya F., Grace A.A., Howes O.D., Allen P., McGuire P. (2021) Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes. Neuropsychopharmacology 2021 May 3. Online ahead of print. IF 6.8, cites 0

Gangadin S., Cahn W., Scheewe T.W., Hulshoff Pol H.E., Bossong M.G. (2021) Reduced resting state functional connectivity in the hippocampus-midbrain-striatum network of schizophrenia patients. Journal of Psychiatric Research 138, 83-8. IF 3.7, cites 0

Batalla A., Bos J., Postma A., Bossong M.G. (2021) The impact of cannabidiol on human brain function: A systematic review. Frontiers in Pharmacology In press. IF 4.2, cites 0   

2020

Egerton A., Grace A.A., Stone J., Bossong M.G., Sand M., McGuire P. (2020) Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development. Schizophr Res 223, 59-70. IF 3.8, cites 0      

Gifford G., Crossley N., Morgan S., Kempton M.J., Dazzan P., Modinos G., Azis M., Samson C., Bonoldi I., Quinn B., Smart S.E., Antoniades M., Bossong M.G., Broome M.R., Perez J., Howes O.D., Stone J.M., Allen P., Grace A.A., McGuire P. (2020) Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis. Human Brain Mapping 2020 Oct 13; Online ahead of print. IF 4.4, cites 0   

Brunt T.M., Bossong M.G. (2020) The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. Eur J Neurosci 2020 Sep 24; Online ahead of print. IF 3.1, cites 1      

Davies C., Wilson R., Appiah-Kusi E., Blest-Hopley G., Brammer M., Perez J., Murray R.M., Allen P., Bossong M.G., McGuire P., Bhattacharyya S. (2020) A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry 10, 311. IF 5.3, cites 0   

Modinos G., Allen P., Zugman A., Dima D., Azis M., Samson C., Bonoldi I., Quinn B., Gifford G.W.G., Smart S.E., Antoniades M., Bossong M.G., Broome M.R., Perez J., Howes O.D., Stone J.M., Grace A.A., McGuire P. (2020) Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome. Schizophr Bull. 46, 670-9. IF 8.0, cites 3

Van der Steur S.J., Batalla A., Bossong M.G. (2020) Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review. Brain Sci. 10, 97. IF 3.3, cites 1  

Daniju Y., Bossong M.G., Brandt K., Allen P. (2020) Do the effects of cannabis on the hippocampus and striatum increase risk for psychosis? Neurosci Biobehav Rev. 112, 324-35. IF 8.3, cites 0 

Appiah-Kusi E., Petros N., Wilson R., Colizzi M., Bossong M.G., Valmaggia L., Mondelli V., McGuire P., Bhattacharyya S. (2020) Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl) 237, 1121-30. IF 4.3, cites 6